Related references
Note: Only part of the references are listed.NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).
Zev A. Wainberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2023)
Promising survival and disease control in third-line or greater metastatic or locally advanced pancreatic cancer patients following chemoradiation and novel combination of aldoxorubicin, N-803 IL-15 superagonist, and PDL1-NK cell therapy
Tara Elisabeth Seery et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
Tai-Jan Chiu et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES (2022)
Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma
George Kim et al.
CURRENT MEDICAL RESEARCH AND OPINION (2022)
Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer br
Tomohisa Otsu et al.
ANTICANCER RESEARCH (2022)
Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study
Shun Tezuka et al.
PANCREATOLOGY (2022)
5-Fluorouracil/L-Leucovorin Plus Oxaliplatin (FOLFOX) Regimen as Salvage Chemotherapy for Patients with Unresectable Pancreatic Cancer Receiving Gemcitabine and Nab-Paclitaxel and 5-Fluorouracil/L-Leucovorin Plus Nanoliposomal Irinotecan: Preliminary Results from Clinical Practice
Takuo Yamai et al.
CURRENT ONCOLOGY (2022)
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
H. S. Park et al.
ESMO OPEN (2021)
Efficacy and tolerability of the combination of nano-liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic adenocarcinoma: post-approval clinic experience
Anup Kasi et al.
JOURNAL OF GASTROINTESTINAL ONCOLOGY (2021)
Folfirinox versus gemcitabine-cisplatin combination as first-line therapy in treatment of pancreaticobiliary cancer
Neslihan Kayahan et al.
TURKISH JOURNAL OF MEDICAL SCIENCES (2021)
Pancreatic Adenocarcinoma, Version 2.2021
Margaret A. Tempero et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2021)
Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
Kyunghye Bang et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
James E. Frampton
DRUGS (2020)
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors
Andrea Wang-Gillam et al.
EUROPEAN JOURNAL OF CANCER (2019)
Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives
Wonhee Woo et al.
ONCOTARGETS AND THERAPY (2019)
Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
Li-Tzong Chen et al.
CANCERS (2019)
Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches
Michael Orth et al.
RADIATION ONCOLOGY (2019)
Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
Changhoon Yoo et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience
Danielle C. Glassman et al.
BMC CANCER (2018)
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Femke M. de Man et al.
CLINICAL PHARMACOKINETICS (2018)
Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review
Fausto Petrelli et al.
EUROPEAN JOURNAL OF CANCER (2017)
Current status on the place of FOLFIRINOX in metastatic pancreatic cancer and future directions
Aurelien Lambert et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2017)
Liposomal irinotecan in gemcitabine-refractory metastatic pancreatic cancer: efficacy, safety and place in therapy
Emma Kipps et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
Yvette N. Lamb et al.
DRUGS (2017)
Nanomedicine developments in the treatment of metastatic pancreatic cancer: focus on nanoliposomal irinotecan
Andrew H. Ko
INTERNATIONAL JOURNAL OF NANOMEDICINE (2016)
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
Andrea Wang-Gillam et al.
LANCET (2016)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial
David Goldstein et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2015)
c-Myc -: Induced chemosensitization is mediated by suppression of cyclin D1 expression and nuclear factor-κB activity in pancreatic cancer cells
Hector Biliran et al.
CLINICAL CANCER RESEARCH (2007)
Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy
DC Drummond et al.
CANCER RESEARCH (2006)
Phase II study of gemcitabine plus docetaxel in advanced pancreatic cancer: A Hoosier Oncology Group study
BP Schneider et al.
ONCOLOGY (2003)